Development and validation of LC‐MS/MS method for simultaneous determination of sofosbuvir and daclatasvir in human Plasma: Application to pharmacokinetic study
- 29 January 2018
- journal article
- research article
- Published by Wiley in Biomedical Chromatography
- Vol. 32 (6) , e4186
Abstract
A simple and highly sensitive liquid chromatography–tandem mass spectrometry (LC‐MS/MS) bioanalytical method was developed and fully validated for the first time for the simultaneous determination of newly discovered antiviral drugs, namely sofosbuvir (SOF) and daclatasvir (DAC) in human plasma. Tadalafil (TAD) was used as internal standard (IS). SOF, DAC and TAD (IS) were extracted from plasma using liquid–liquid extraction technique with methyl tert‐butyl ether. The chromatographic separation was carried out using ZorbaxSB‐C18 column (4.6 × 50 mm,5 μm) and 5 mm ammonium formate buffer (pH 3.5)–acetonitrile (50:50, v/v) as mobile phase in an isocratic elution mode pumped at a flow rate 0.7 mL min−1. The quantitation was performed on API4500 triple quadrupole tandem mass spectrometer with positive electrospray ionization interface in multiple reaction monitoring mode. Validation was applied according to US Food and Drug Administration guidelines for bio‐analytical methodswith respect to linearity, precision, accuracy, selectivity, carry‐over, stability and dilution integrity. Linearity was obtained over concentration ranges of 0.3–3000 and 3–3000 ng mL−1 for SOF and DAC, respectively, by applying a weighted least‐squares linear regression method (1/x2). The proposed method could be applied successfully in bioequivalence and/or clinical studies for therapeutic drug monitoring of patients undergoing dual combination therapy as the latter combination proved more efficacious and powerful tool for the complete treatment of hepatitis C genotype 3 within 16 weeks. The suggested method has been applied successfully to pharmacokinetic studies with excellent assay ruggedness and reproducibility.Keywords
This publication has 27 references indexed in Scilit:
- Development a validated highly sensitive LC–MS/MS method for simultaneous quantification of Ledipasvir, sofosbuvir and its major metabolite GS-331007 in human plasma: Application to a human pharmacokinetic studyJournal of Pharmaceutical and Biomedical Analysis, 2017
- Reversed-Phase Liquid Chromatographic Method for Determination of Daclatasvir Dihydrochloride and Study of Its Degradation BehaviorChromatographia, 2017
- Validated stability-indicating HPLC-DAD method for determination of the recently approved hepatitis C antiviral agent daclatasvirAnnales Pharmaceutiques Françaises, 2017
- Electrochemical design of a new nanosensor based on cobalt nanoparticles, chitosan and MWCNT for the determination of daclatasvir: a hepatitis C antiviral drugRSC Advances, 2017
- The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatmentLiver International, 2016
- Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C: pilot studyJournal of Viral Hepatitis, 2016
- A UHPLC–MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasmaJournal of Pharmaceutical and Biomedical Analysis, 2016
- Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis CClinical Pharmacokinetics, 2016
- Multiplexed LC-MS/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasmaJournal of Pharmaceutical and Biomedical Analysis, 2015
- Hepatitis C Virus NS5A Replication Complex Inhibitors: The Discovery of DaclatasvirJournal of Medicinal Chemistry, 2014